← All trials
NCT06925321
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 26, 2025
- Primary completion
- Feb 29, 2028
- Completion date
- Feb 29, 2028
- First posted
- Apr 13, 2025
- Last posted
- Nov 25, 2025
- Enrollment
- 219
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Basilea PharmaceuticaLead sponsor
- Department of Health and Human ServicesCollaborator
- Basilea PharmaceuticaOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.